| Literature DB >> 35453770 |
Mengyuan Li1, Yi-Xin Huo1, Shuyuan Guo1.
Abstract
Nonmodel microbes with unique and diverse metabolisms have become rising stars in synthetic biology; however, the lack of efficient gene engineering techniques still hinders their development. Recently, the use of base editors has emerged as a versatile method for gene engineering in a wide range of organisms including nonmodel microbes. This method is a fusion of impaired CRISPR/Cas9 nuclease and base deaminase, enabling the precise point mutation at the target without inducing homologous recombination. This review updates the latest advancement of base editors in microbes, including the conclusion of all microbes that have been researched by base editors, the introduction of newly developed base editors, and their applications. We provide a list that comprehensively concludes specific applications of BEs in nonmodel microbes, which play important roles in industrial, agricultural, and clinical fields. We also present some microbes in which BEs have not been fully established, in the hope that they are explored further and so that other microbial species can achieve arbitrary base conversions. The current obstacles facing BEs and solutions are put forward. Lastly, the highly efficient BEs and other developed versions for genome-wide reprogramming of cells are discussed, showing great potential for future engineering of nonmodel microbes.Entities:
Keywords: CRISPR/Cas9; base editing; gene engineering; in vivo evolution; nonmodel microbes
Year: 2022 PMID: 35453770 PMCID: PMC9024924 DOI: 10.3390/biology11040571
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1The process of gene editing using CRISPR/Cas9 and a BE. (A) Directed by gRNA, CRISPR/Cas9 recognizes the PAM site (5′-NGG-3′, highlighted in red) and introduces DSBs at the target. DSBs induces two cellular DNA repair systems, NHEJ and HR. Through NHEJ, a few imprecise indels are created through error-prone DNA repair. Through HR, the target is replaced by homologous donor DNA with desired edits and is therefore introduced with deletions, insertions, or substitutions of nucleotides. (B) The BE is also directed by gRNA to the target. At the target, deaminase enzyme achieves base conversion without causing DSBs and requiring donor DNA. CBE mediates the conversion of a C:G base pair to a T:A, which can replace four codons (CAA, CAG, CGA, TGG) with premature stop codons (TAA, TAG, TGA) to inactivate the gene. ABE mediates the base conversion from an A:T base pair to G:C, which can replace start codon ATG with GTG or ACG to disrupt the initiation of gene translation. Other than point mutation, BEs can achieve multiplex gene editing, in vivo evolution of protein and strain, metabolic engineering, etc., in various microbes, as discussed in detail below.
Figure 2Phylogenetic tree of all microbes that have been researched by BEs, based on small-subunit rRNA sequences and constructed using the maximum-likelihood estimation. The phylogenetic tree includes 21 genera and six classes which are shadowed in different colors. (A) Microbes belong to the kingdom Fungi, phylum Ascomycota, and class Saccharomycetes. Saccharomyces and Kluyveromyces belong to the same family, Saccharomycetaceae, highlighted in brown. Yarrowia and Aspergillus belong to the same family, Dipodascaceae, highlighted in yellow. (B) Microbes belong to the kingdom Bacteria, phylum Proteobacteria, and class Alphaproteobacteria. Rhodobacter and Brucella belong to the family Rhodobacteraceae and Rhizobiaceae, respectively. Agrobacterium and Sinorhizobium belong to the same family, Brucellaceae, highlighted in purple. (C) Microbes belong to the kingdom Bacteria, phylum Proteobacteria, and class Gammaproteobacteria. Pseudomonas, Acinetobacter, and Shewanella belong to the family Pseudomonadaceae, Moraxellaceae, and Shewanellaceae, respectively. Escherichia and Klebsiella belong to the same family, Enterobacteriaceae, highlighted in pink. (D) Microbes belong to the kingdom Bacteria, phylum Actinobacteria, and class Actinomycetia. Streptomyces, Mycobacterium, and Corynebacterium belong to the family Streptomycetaceae, Corynebacteriaceae, and Mycobacteriaceae, respectively. (E) Genus Clostridium belongs to the kingdom Bacteria, phylum Firmicutes, class Clostridia, and family Clostridiaceae. (F) Microbes belong to kingdom Bacteria, phylum Firmicutes, and class Bacilli. Paenibacillus, Companilactobacillus, Staphylococcus, and Bacillus belong to the family Paenibacillaceae, Lactobacillaceae, Staphylococcaceae, and Bacillaceae, respectively.
Developed Versions of BEs to Overcome Editing Limitations in Microbes.
| BE type | Year | Fusing Enzyme | Cas9 Protein | gRNA | Construct | Improved Editing Activity | Applications | Refs |
|---|---|---|---|---|---|---|---|---|
| To narrow the editing window | ||||||||
| CBE | 2019 | PmCDA1 with a series of C-terminal truncations | nCas9D10A | 20 nt | PmCDA1 variants-nCas9-UGI | Prefer to edit at positions −17 to −18 while retaining editing efficiency | Edit polyC motifs and Can1 to test narrow editing windows of C-terminal truncations such as CDA1Δ190, Δ192, Δ194 in | [ |
| CBE | 2020 | APOBEC3A with a series of C-terminal truncations and mutations | nCas9D10A | 20 nt | APOBEC3A variants-nCas9-UGI | Prefer to edit at positions −15 to −16 with decreased off-target RNA editing | Edit Can1 to test editing activity of APOBEC3A truncations such as Δ182, Δ186 and Δ190 in | [ |
| To expand the editing range | ||||||||
| CBE | 2019 | PmCDA1 | nVQRD10A, nVRERD10A, nxCas9D10A, nCas9-NGD10A | 20 nt | nCas9 variants-PmCDA1 | Recognize the targets at non-NGG PAM with high editing efficiency | Introduce an amino acid transition T311I of LysC to obtain the mutant strain with 1.7 g/L lysine production in | [ |
| nCas9D10A | 18–30 nt | nCas9-PmCDA1 | Increase editing efficiency at positions −14 and −15 by using 18 nt gRNA; increase efficiency at position −21 by using 22 and 24 nt gRNA | Edit poly C motifs in the plasmids and chromosomes of | ||||
| CBE | 2020 | PmCDA1 | nVQRD10A, nVRERD10A, nxCas9D10A, nCas9-NGD10A | 20 nt | PmCDA1 variants-nCas9 variants-UGI | Recognize the targets at non-NGG PAM with a relatively narrow editing window from −17 to −18 | Edit polyC motifs to test the availability of Cas9 variants, editing efficiency, and window in | [ |
| CBE | 2021 | PmCDA1 | dCas9 | 20 nt | dCas9-PmCDA1-UGI | Broaden the editing window from −16 to −20 with 100% efficiency and increase the multiplex gene editing efficiency to 75.5% for quintuple targets by adding UGI | Test five different constructs of CBE in | [ |
| CBE | 2021 | PmCDA1 | nCas9D10A | 20 nt | PmCDA1-nCas9-UGI (integrated into genome) | Broaden the editing window at position −15 to −20 with 97–100% efficiency | In situ mutate Sec-translocase and BceB protein to obtain mutant strains with 3.6-fold transportation efficiency and different sensitivity to bacitracin, respectively, in | [ |
| 21–26 nt | Increase editing efficiency by using 21 and 22 nt gRNA; expand editing window from −15 to −22 by using 23–26 nt gRNA; | |||||||
| 20 nt with a stem loop at 3‘ end of gRNA | increase the editing efficiency at position −15 from 70% to 87% | |||||||
| To decrease the off-target effect | ||||||||
| CBE | 2020 | rAPOBEC1 variants | dCas9 | 20 nt | rAPOBEC1 variants-dCas9-UGI | Balance efficient, on-target editing with greatly decreased gRNA-independent editing | Develop multiple rapid, cost-effective methods to screen the propensity of different deaminase variants and engineer the YE1 variants that retain high editing activity with minimal gRNA-independent off-target editing | [ |
| CBE | 2021 | tCDA1EQ (PmCDA1Δ30-150, W122E, W133Q) | nCas9D10A | 20 nt | tCDA1EQ-nCas9 | Significant decrease (5–79 fold) gRNA-independent off-target effects with comparable editing efficiency to original CBE | Edit | [ |
| nCas9 1054aa-tCDA1EQ-1055aa (inlaid architecture) | ||||||||
| CBE | 2021 | rAPOBEC1 | nCas9D10A | 20nt with H12-B3-P5 (a 3 nt bubble positioned from positions 5 to 7 into a 12 nt hairpin) | rAPOBEC1-nCas9-UGI | Significantly decrease off-target editing without sacrificing on-target editing efficiency | Test editing efficiency and gRNA-dependent off-targets in | [ |
| ABE | ecTadA-TadA* | 20 nt with H12-B3-P4 | ecTadA-TadA*-nCas9 | |||||
| To achieve DNA base transversion | ||||||||
| PE | 2021 | M-MLV (reverse transcriptase) | nCas9H840A | 20 nt with 13–17 nt PBS and 13 nt RTT | nCas9-M-MLV2 | Substitutions, insertions, and deletions with 6.8%, 12.2% and 26% efficiency, respectively, in chromosome with few bystanders and off-targets | Achieve gene substitutions, deletions (up to 97 bp), insertions (up to 33 bp), and multiplex editing in | [ |
| GBE | 2021 | PmCDA1 | nCas9D10A | 20 nt | UNG-nCas9-PmCDA1 | Convert C to A with an average editing efficiency of 87.2% ± 6.9% with no detectable gRNA-dependent off-target | Convert C to A at four loci in | [ |
The Characteristics and Applications of BEs in Nonmodel Microbes.
| Species | Major Function | Type | Year | gRNA Promoter | Construct of Fusion Protein | PAM | Editing Window | Editing Efficiency | Multiplex Gene Editing | Applications of BEs | Off-Targets | Refs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Industrially Important Microbes | ||||||||||||
|
| Industrial production of various enzymes, chemicals, and macromolecules, as well as the utilization of cell biomass | CBE | 2017 | PSNR52 | PTSNR52 | NGG | −17 to −18 | 12.5–25% | nr | Inactivate | nr | [ |
| An excellent bacterial host to produce polymers, bulk chemicals, drugs, and high-price specialties | CBE | 2018 | Ptrc | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 100% | nr | Inactivate genes in | nd in the six similar spacers of the | [ | |
|
|
|
|
|
| [ | |||||||
|
|
|
|
| |||||||||
| CBE | 2020 | Pj23119 | ParaBAD-rAPOBEC1-eSpCas9ppD10A | NGG | nr | 20% | nr | Edit | nr | |||
| CBE | 2020 | Pj23119 | Pm-rAPOBEC1-eSpCas9ppD10A-UGI | NGG | −13 to −18 | 40–60% | nr | nr | ||||
| CBE | 2020 | Pj23119 | ParaBAD-rAPOBEC1-eSpCas9ppD10A-UGI | NGG | −13 to −18 | 80–100% | 100% for double targets and 35% for triple targets | Inactivate genes in | nd by Sanger sequencing the potential sites predicted by CasOT | |||
| CBE | 2020 | Pj23119 | ParaBAD-rAPOBEC1-eSpCas9ppD10A-NG-UGI | NG | −13 to −18 | 100% | 100% for double targets recognized by eSpCas9pp and eSpCas9-NG in a two-plasmid system | Inactivate | nr | |||
| CBE | 2020 | Pj23119 | ParaBAD-YE1-eSpCas9ppD10A-UGI | NGG | −14 to −17 | 62.5% | nr | Precisely edit | nr | |||
|
| GRAS and industrial production of lipase and organic acids | CBE | 2019 | PSCR1’-tRNAGly | PUAS1B8-TEF(136)-nCas9D10A-PmCDA1-UGI | NGG | −14 to −20 | 28% | 6.7% for double targets | Inactivate | nr | [ |
| CBE | 2019 | PSCR1’-tRNAGly | PTEFin-nCas9D10A-PmCDA1-UGI | NGG | −14 to −20 | 94.3 ± 5% | 31% for double targets | nr | ||||
| Industrial production of bioactive secondary metabolites, such as antifungals, antivirals, antitumorals, anti-hypertensives, and mainly antibiotics, etc. | CBE | 2019 | PermE* | PtipA-rAPOBEC1-nCas9D10A-UGI | NGG | −11 to −17 | 30–100% | 33.3% for triple targets | Substitute amino acids in SCO5087 and SCO5092; inactivate genes of BGCs in nonmodel strain | 38–56 by WGS (24–34 meaningful amino acid changes); whereas 29 SNVs in wild-type strain (18 amino acid changes); | [ | |
| ABE | 2019 | PermE* | PtipA-TadA-TadA*-nCas9D10A-UGI | NGG | −12 to −17 | 0–100% | nr | Target SCO5087 and a designed matrix containing NA motifs to test efficiency and preference | 27–33 by WGS (20–21 meaningful amino acid changes) | |||
| CBE | 2019 | PkasO* | PrpsL-rAPOBEC1-dCas9-UGI | NGG | −13 to −17 | 43–70% | 43% for double targets | Edit | nr | [ | ||
| CBE | 2019 | PkasO* | PrpsL-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 100% | 100% for double targets; 60% for quintuple targets | Simultaneously disrupt the genes of polyketide synthase clusters to increase production of avermectin | 3 by Sanger sequencing the sites predicted by CasOT; | |||
| CBE | 2019 | PkasO* | PrpsL-rAPOBEC1-HF-nCas9D10A-UGI | NGG | −13 to −17 | 80% | nr | Edit | nd by Sanger sequencing the sites mentioned above | |||
|
|
|
|
|
| ||||||||
| ABE | 2019 | PkasO* | PrpsL-TadA-TadA*-nCas9D10A | NGG | −14 to −17 | 100% | nr | Disrupt the initiation of | nr | |||
|
|
|
|
|
| [ | |||||||
| CBE | 2019 | Pj23119 | PtipAp-dCas9-PmCDA1-UL | NGG | −16 to 20 | 10–100% | 60% for double targets; 20% for triple targets | Inactivate genes in | 1 by Sanger sequencing the potential sites predicted by Cas-OFFinder | |||
| CBE | 2019 | Pj23119 | PtipAp-nCas9D10A-PmCDA1-UL | NGG | −16 to 20 | 15% | nr | Edit | nr | |||
| CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-dCas9-UGI | NGG | −13 to −18 | 1–20% | nr | Edit | 16.50 ± 8.35 by WGS | [ | ||
| CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −18 | 3–25% | nr | nr | ||||
| CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-dCas9-UGI with asRNA | NGG | −13 to −18 | 21.2–65.8% | nr | 13.50 ± 3.32 by WGS | ||||
| CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-nCas9D10A-UGI with asRNA | NGG | −13 to −18 | 26.2–79.4% | nr | nr | ||||
|
| Production of acetone, n-butanol, isopropanol etc. | CBE | 2019 | Pj23119 | Pthl-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 20–100% | nr | Edit | nr | [ |
|
| Production of acetic acid and ethanol from waste gas | CBE | 2020 | Pj23119 | P2TetO1-dCas9-PmCDA1-UL | NGG | −11 to −19 | 2–55.6% | nr | Inactivate | nr | [ |
|
| Industrial production of CoQ10, isoprenoids, poly-β-hydroxybutyrate, hydrogen | CBE | 2020 | Pj23119 | PLac-dCas9-PmCDA1-UL | NGG | −14 to 20 | 16.7% | nr | Inactivate | nr | [ |
| CBE | 2020 | Pj23119 | PLac-nCas9D10A-PmCDA1-UL | NGG | 14 to 20 | 10–96.7% | 43% for double targets; 46.7% for triple targets | Inactivate | nr | |||
| ABE | 2020 | Pj23119 | PLac-TadA-TadA*-dCas9 | NGG | −14 to −16 | 0–5% | nr | Edit | nr | |||
| ABE | 2020 | Pj23119 | PLac-TadA-TadA*-nCas9D10A | NGG | −14 to −16 | 0–30% | nr | Edit | nr | |||
|
| Bioelectricity production from biomass wastes | CBE | 2020 | Ptac | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 33.3–100% | 87.5% for double targets | Target NC motifs to test editing preference; inactivate | nr | [ |
|
| Production of bacteriocin and 3-phenyllactic acid | CBE | 2021 | P3 | PsppA-rAPOBEC1-nCas9D10A | NGG | −14 to −18 | 75–100% | nr | Edit seven C-rich spacer sequences in a plasmid to test editing window and efficiency | nr | [ |
|
| ||||||||||||
|
| Nitrogen fixation, plant growth promotion, soil phosphorus solubilization and production of cxopolysaccharides, hydrolytic enzymes, antibiotics, and cytokinin |
|
|
|
|
| [ | |||||
| CBE | 2021 | Para | Pspac-dCas9-PmCDA1-UGI | NGG | −16 to 20 | 100% | 100% for double and triple targets; 83.3% for quadruple targets; 75.5% for quintuple targets | Disrupt genes of five known BGCs to reveal the antimicrobial spectrum of the novel antibiotics in the sixth unknown BGCs | 8.5 SNVs including 4.2 amino acid changes by WGS | |||
| Nature’s genetic engineer for diverse species including crops |
|
|
|
|
| [ | ||||||
| CBE | 2021 | Pj23119 | PvirB-dCas9-PmCDA1-UL | NGG | −15 to −19 | 91% | 80% for double targets | Inactivate | nr | |||
|
| Perform symbiotic nitrogen fixation within leguminous host plants such as alfalfa, an important forage crop |
|
|
|
|
| [ | |||||
| ABE | 2021 | PRpsT | PHemA-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 60% | nr | Edit | nr | |||
| ABE | 2021 | PRpmJ | PHemA-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 100% | 90% for triple targets | Edit | nd by Sanger sequencing the potential sites predicted by Cas-OFFinder | |||
| ABE | 2021 | PRpmJ | PNeo-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 100% | ||||||
| ABE | 2021 | PRpmJ | PTau-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 80% | ||||||
| CBE | 2021 | PRpmJ | PHemA-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 75% | nr | Inactivate | ||||
| CBE | 2021 | PRpmJ | PTau-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 100% | nr | |||||
| CBE | 2021 | PRpmJ | PHemA-nCas9D10A-PmCDA1-UGI | NGG | −13 to −20 | 100% | 80% for double targets; 50–70% for triple targets | Edit | ||||
| GBE | 2021 | PRpmJ | PHemA-nCas9D10A-PmCDA1-UNG | NGG | −14 to −18 | 33–80% | nr | nr | ||||
|
| ||||||||||||
|
| The most important agent of human brucellosis | CBE | 2018 | PLlacO-1 | Ptrc-rAPOBEC1-nCas9D10A-UGI-NLS | NGG | −15 | 100% | nr | Inactivate | nr | [ |
|
| Cause pneumonia, bloodstream infections, wound, or surgical site infections and meningitis; biosynthesize 1,3-propanediol and 2,3-butanediol | CBE | 2018 | Pj23119 | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 100% | nr | Edit | nr | [ |
|
| Cause infections ranging from skin infections to severe systemic infections | CBE | 2018 | Pcap 1A | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −17 | 100% | nr | Inactivate | nr | [ |
| ABE | 2020 | Pcap 1A | PrpsL-ecTadA-TadA*-nCas9D10A | NGG | −13 to −17 | 50–100% | 100% for double targets | Screen key residues of cntBC targeted by 38 gRNAs to obtain 42 mutant strains | nd gRNA-dependent off-target by WGS | [ | ||
|
| causing ventilator-associated pneumonia and bloodstream infections, and mortality rates can reach 35% | CBE | 2019 | Pj23119 | P | NGG | −13 to −18 | 20–100% | nr | Edit | nr | [ |
| Causes tuberculosis, getting 10 million infections and 1.45 million deaths in 2018 worldwide | CBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9 | NNRGAA | nr | 4–15% | nr | Test availability of dSt1Cas9-BE in | nr | [ | |
| CBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9-UGI-UGI | NNRGAA | nr | 12–95% | nr | Inactivate | nr | |||
| CBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9evolve-UGI-UGI | NNNNAA | −10 to −14 | 20–95% | 87.5% for both double and triple targets | Inactivate the essential L-leucine biosynthesis genes | nd gRNA-dependent off-target by WGS | |||
| GBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9-UNG | NNRGAA | nr | 100% | nr | Edit five different loci to test editing efficiency | nr | |||
| GBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9evolve-UNG | NNNNAA | −13 to −16 | 20–65% | 75% for triple targets | Edit 29 endogenous genomics sites to find only TC motif is available for editing | nr | |||
| CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-dSt1Cas9-UGI | NNAGGAC | nr | 1.2% | nr | Inactivate | nr | [ | ||
| CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-nSt1Cas9-UGI | NNAGGAC | nr | 10.3% | nr | nr | ||||
| CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-nSt1Cas9-UGI with assistant plasmid expressing recX | NNAGGAC | −12 to −18 | 37.5–100% | nr | nr | ||||
| CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-nSt1Cas9-UGI with assistant plasmid expressing recX and nucSE107A | NNAGGAC | nr | 12.5–75% | nr | Inavtivate | nr | |||
nr: not reported, nd: not detected, na: not available, UL: UGI-LVA (protein degradation tag), SNVs: single-nucleotide variants, WGS: whole-genome sequencing, GRAS: generally recognized as safe, BGC: biosynthetic gene cluster. The construct of BEs that failed to work in microbes are marked in red.
Figure 3The basic components and working mechanisms of CRISPR-mediated base editing systems. The common editing windows are highlighted in dark red in the DNA sequence. (A) CBE consists of cytosine deaminase (PmCDA1 in (A)), impaired Cas9, gRNA, and UGI (inhibits uracil DNA glycosylase, abbreviated to UNG, to improve the efficiency of CBE but is not essential). Under the R-loop, CBE deaminates C to U. If UNG removes U, the apurinic/apyrimidinic (AP site) will soon be reversed to C. If UGI is added to CBE, U will be retained at the locus where DNA polymerase will read U as T. The C:G is successfully conversed to T:A. If dCas9 is replaced with nCas9, the nonedited strand will be nicked. Without the inhibition of UGI, U will be removed at the other strand, where AP endonuclease nicks the edited strand and leads to DSBs, bringing indels or cell death. (B) ABE consists of impaired Cas9, gRNA, and ecTadA–TadA* homodimer (ecTadA: wild-type tRNA adenosine deaminase from E. coli, TadA*: evolved ecTadA that can operate on DNA). ABE deaminates A to I at the target, where I is misread as G by DNA polymerase. (C) PE consists of nCas9, reverse transcriptase (RT), and prime editing gRNA (pegRNA). PegRNA comprises two essential parts: PBS (primer binding site) and RTT (reverse transcriptase template). PE nicks the edited strand. The strand then hybridizes with PBS and extends with the copy of RTT by RT so that the mutation is introduced to the strand. The 5′ flap intermediate is removed by flap endonuclease, and the 3′ flap is ligated. The desired edits are consequently introduced into the DNA sequence. (D) GBE consists of nCas9, PmCDA1, and UNG in E. coli. GBE deaminates the C at the edited strand and nicks the other strand. U is removed by UNG, so the target becomes an AP site where TLS polymerases assemble and extend the nicked strand by Polζ. When passing by the locus opposite to the AP site, Rev1 cooperates with C and Polδ with T, which results in the creation of G:C and A:T, respectively, after DNA repair or replication.
Figure 4Current development of BEs in different microbial species. (A) In theory, any base pair could be converted to any of the others, which only takes three steps at most using the combination of ABE, CBE, and GBE. Firstly, C:G and T:A can be converted to each other by CBE and ABE. Secondly, C:G can be converted to G:C or A:T by GBE. (a) If C:G is predominantly converted to A:T by GBE, the most complicated editing step, shaded in grey, is from A:T to C:G, by firstly converting A:T to G:C by ABE, then to T:A by GBE, and finally to C:G by ABE. (b) If C:G is predominantly converted to G:C by GBE, the most complicated conversion, shaded in grey, is from A:T to T:A, firstly converting A:T to G:C by ABE, then to C:G by GBE, and finally converting to T:A by CBE. (B) The establishment of BEs in different microbes are listed in the table. The achieved base conversions are drawn with a solid line, and base conversions that have not been completed in some microbes are drawn with a dotted line.